ANNOUNCEMENT 23 Jul 2020

On 23 July 2020, the UK government announced investing GBP 100 million on a new vaccine center to accelerate the mass production of a successful COVID-19 vaccine in the UK.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

UK Department for Business, Energy & Industrial Strategy, Press Release, “Over £100 million cash boost to manufacture millions of doses of COVID-19 vaccine”. Available at: https://www.gov.uk/government/news/over-100-million-cash-boost-to-manufacture-millions-of-doses-of-covid-19-vaccine

Cell and Gene Therapy Catapult. Available at: https://ct.catapult.org.uk/

Inception date: 23 Jul 2020 | Removal date: open ended

Financial grant

On 23 July 2020, the UK government announced investing GBP 100 million (USD 127.3 million) on a new vaccine center to accelerate the mass production of a successful COVID-19 vaccine in the UK. The new center which is called the Cell and Gene Therapy Catapult Manufacturing Innovation Centre is planned to be opened in December 2021 and will have the capacity to produce millions of vaccine doses each month. The government also announced investing an additional GBP 4.7 million (USD 6 million) for new training facilities and an online learning platform to boost vaccine and cell and gene therapy skills.

Apart from addressing the immediate need to produce a Coronavirus vaccine, the new vaccine and gene therapy center also aims to strengthen the UK cell and gene therapy industry, as well as develop cutting-edge therapies to diseases, such as diabetes, heart disease, and cancer. This new investment is also expected to serve the UK's economic recovery after the COVID-19 pandemic by creating new, high-skilled jobs. 

The new center will complement the Vaccines Manufacturing and Innovation Centre (VMIC) which received GBP 93 million investment from the government in May 2020 (see related state act).

Concerning the investment, Business Secretary Alok Sharma stated that: “We are taking all necessary steps to ensure we can vaccinate the public as soon as a successful COVID-19 vaccine becomes available. This new Cell and Gene Therapy Catapult Manufacturing Innovation Centre, alongside crucial investment in skills, will support our efforts to rapidly produce millions of doses of a coronavirus vaccine while ensuring the UK can respond quickly to potential future pandemics.”

The CEO of the Cell and Gene Therapy Catapult Matthew Durdy said: “This commitment from the government through the Vaccines Taskforce will enable continued growth and productivity in the cell and gene therapy sector, as well as providing vital resource for vaccine manufacturing and economic recovery from the COVID-19 pandemic. We are delighted to be able to deploy the specialist capabilities of the Cell and Gene Therapy Catapult in such an important initiative. Accelerating the availability of COVID-19 vaccines, increasing skills and employment, and facilitating growth of the advanced medicines industry will make a valuable contribution to the recovery of the economy.

The Cell & Gene Therapy Catapult is an independent center of excellence to advance the growth of the UK cell and gene therapy.

AFFECTED SECTORS

 

AFFECTED PRODUCTS